56 related articles for article (PubMed ID: 38611004)
1. Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival.
Kuklinski D; Blum M; Subelack J; Geissler A; Eichenberger A; Morant R
Breast Cancer Res; 2024 May; 26(1):84. PubMed ID: 38802897
[TBL] [Abstract][Full Text] [Related]
2. Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.
Chuang SL; Chen SL; Yu CP; Chang KJ; Yen AM; Chiu SY; Fann JC; Tabár L; Stephen DW; Smith RA; Chen HH
APMIS; 2014 Aug; 122(8):699-707. PubMed ID: 25046200
[TBL] [Abstract][Full Text] [Related]
3. Lead-Time Corrected Effect on Breast Cancer Survival in Germany by Mode of Detection.
Schumann L; Hadwiger M; Eisemann N; Katalinic A
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611004
[TBL] [Abstract][Full Text] [Related]
4. Isolating the effect of confounding from the observed survival benefit of screening participants - a methodological approach illustrated by data from the German mammography screening programme.
Buschmann L; Wellmann I; Bonberg N; Wellmann J; Hense HW; Karch A; Minnerup H
BMC Med; 2024 Jan; 22(1):43. PubMed ID: 38287392
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
[TBL] [Abstract][Full Text] [Related]
7. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias.
Lawrence G; Wallis M; Allgood P; Nagtegaal ID; Warwick J; Cafferty FH; Houssami N; Kearins O; Tappenden N; O'Sullivan E; Duffy SW
Breast Cancer Res Treat; 2009 Jul; 116(1):179-85. PubMed ID: 18622697
[TBL] [Abstract][Full Text] [Related]
8. Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
Kregting LM; Olthof EMG; Breekveldt ECH; Aitken CA; Heijnsdijk EAM; Toes-Zoutendijk E; de Koning HJ; van Ravesteyn NT
Eur J Cancer; 2022 Nov; 175():180-186. PubMed ID: 36126478
[TBL] [Abstract][Full Text] [Related]
9. Estimating Age-Specific Mean Sojourn Time of Breast Cancer and Sensitivity of Mammographic Screening by Breast Density among Korean Women.
Choi E; Suh M; Jung SY; Jung KW; Park S; Jun JK; Choi KS
Cancer Res Treat; 2023 Jan; 55(1):136-144. PubMed ID: 35381162
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany.
Jansen L; Erb C; Nennecke A; Finke I; Pritzkuleit R; Holleczek B; Brenner H;
Lancet Reg Health Eur; 2021 May; 4():100063. PubMed ID: 34557810
[TBL] [Abstract][Full Text] [Related]
11. Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality.
Dibden A; Offman J; Duffy SW; Gabe R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326646
[TBL] [Abstract][Full Text] [Related]
12. Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies.
Abrahamsson L; Isheden G; Czene K; Humphreys K
Stat Methods Med Res; 2020 Feb; 29(2):374-395. PubMed ID: 30854935
[TBL] [Abstract][Full Text] [Related]
13. Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands).
Aarts A; Duffy SW; Geurts S; Vulkan DP; Otten J; Hsu CY; Chen T; Verbeek A; Broeders M
J Med Screen; 2019 Sep; 26(3):147-153. PubMed ID: 30541383
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
